Corcept Therapeutics Community
Create a narrative
WA
Based on Analyst Price Targets
Korlym's Patent Victory And Diverse Clinical Advances Promise Bright Financial Horizons
US$65.40
FV
32.8% undervalued intrinsic discount23.07%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
about 5 hours agoauthor updated this narrative